Core Viewpoint - The company has approved a plan to utilize temporarily idle raised funds for cash management, allowing for investment in low-risk, liquid financial instruments [1] Group 1: Board Meeting and Approval - The company will hold its third board meeting on February 12, 2026, to review and approve the cash management proposal [1] - The maximum amount for cash management is set at RMB 100 million [1] Group 2: Investment Duration and Conditions - The investment period for the cash management plan is from April 14, 2026, to April 13, 2027, valid for 12 months [1] - The funds can be used in a rolling manner within the approved limit [1] Group 3: Investment Direction - The investment will focus on high-security, liquid financial products such as structured deposits, agreement deposits, notice deposits, time deposits, large certificates of deposit, and income certificates [1] - The funds are not permitted to be used for pledging or for securities investment purposes [1] - The cash management activities will not affect the progress of the fundraising investment projects or the company's normal operations [1]

Core Viewpoint - The company announced the conclusion of certain fundraising projects and the permanent allocation of surplus funds to working capital [1] Group 1: Project Conclusion - The company held its third board meeting on February 12, 2026, where it approved the conclusion of specific fundraising projects [1] - The projects concluded include the "Phase III clinical and post-marketing research project for Aibond® (Ainovelin tablets)" and the "Phase III/IV clinical project for ACC008" [1] - Both projects have reached the predetermined usable status as of the conclusion date [1] Group 2: Financial Details - As of December 31, 2025, the total surplus fundraising amount from the concluded projects is 36.4993 million yuan [1] - The company plans to permanently allocate the surplus funds to working capital [1] - Following the transfer of surplus funds, the company will cancel the corresponding fundraising special account [1]

以上内容基于公开资料整理，不构成投资建议。 经济观察网艾迪药业计划以简易程序向特定对象发行A股股票，拟募集资金不超过1.85亿元，用于收购 控股子公司南京南大药业少数股东股权及补充流动资金，该事项尚需上海证券交易所审核通过及中国证 监会注册。同时，公司拟以约1.3亿元收购南大药业22.2324%的股权，交易完成后持股比例将从 51.1256%增至73.358%，目前尚需市场监督管理部门核准。此外，董事会已审议通过相关议案，但暂不 召开股东大会，将根据整体工作安排适时召开。公司在研产品如AD108注射液和注射用ADB116的研发 工作也在持续推进中。 ...

证券代码：688488 证券简称：艾迪药业 公告编号：2026-015 江苏艾迪药业集团股份有限公司 关于提前归还暂时补充流动资金的闲置募集资金的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏艾迪药业集团股份有限公司（以下简称"公司"）于 2025 年 2 月 27 日 召开了第三届董事会第二次会议，审议通过了《关于使用部分闲置募集资金暂时 补充流动资金的议案》，同意公司及子公司使用部分闲置募集资金不超过人民币 1.50 亿元暂时补充流动资金，仅用于业务拓展、日常经营等与主营业务相关的生 产经营，使用期限自董事会批准之日起不超过 12 个月。 上述具体内容详见公司于 2025 年 2 月 28 日在上海证券交易所网站 （www.sse.com.cn）披露的《江苏艾迪药业集团股份有限公司关于使用部分闲置 募集资金暂时补充流动资金的公告》（公告编号：2025-009）。根据上述决议，公 司在规定期限内实际使用了人民币 1.199 亿元闲置募集资金暂时补充流动资金， 并对资金进行了合理的安排与使用，未影响募集资金投 ...

证券日报网讯 2月3日，艾迪药业在互动平台回答投资者提问时表示，公司股价波动受宏观经济、市场 环境、行业因素及投资者情绪等多重因素影响，具有不确定性。目前公司各项经营活动均正常开展，经 营基本面稳定，不存在应披露而未披露的重大事项。公司管理层始终致力于做好经营管理工作，持续提 升公司核心竞争力，努力为投资者创造长期价值。二级市场股价走势受多方面因素综合作用，敬请广大 投资者理性看待市场波动，注意投资风险。 ...

证券日报网讯 1月28日，艾迪药业在互动平台回答投资者提问时表示，公司股权激励计划的考核指标， 系基于公司长期战略目标与可持续发展能力综合设定，选取净利润、HIV创新药物营业收入作为核心考 核目标，直接锚定公司经营质效与创新药市场表现，是落实核心战略的关键举措，初衷在于充分激发核 心员工的积极性与创新能力，推动其与公司同成长、共发展，促进公司长期经营目标的实现。公司深知 资本市场对股权激励计划的期待，也高度重视投资者的关注，后续将以更扎实的经营行动力争达成业绩 目标，切实回报公司员工与广大投资者的信任与支持。 ...

Market Overview - The A-share market exhibited a fluctuating and differentiated pattern last week, with major indices showing mixed performance and active rotation among hot sectors [1][7] - Institutions generally hold an optimistic outlook, believing the market is likely to trend upward [1][7] - As of January 25, over 950 companies have disclosed their 2025 earnings forecasts, with around 40% of these companies showing positive performance [1][7] Semiconductor Industry - The semiconductor industry, particularly companies related to artificial intelligence, data center construction, and domestic substitution, is expected to see strong earnings growth in 2025 [1][8] - Notable companies include: - Zhongwei Semiconductor expects revenue of approximately 1.122 billion yuan, a year-on-year increase of about 23%, and a net profit of 284 million yuan, up approximately 107% [8] - Juchip Technology anticipates revenue of 922 million yuan, a 41.44% increase, and a net profit of 204 million yuan, up 91.40% [2] - Baiwei Storage forecasts revenue between 10 billion to 12 billion yuan, a growth of 49.36% to 79.23%, and a net profit of 850 million to 1 billion yuan, a staggering increase of 427.19% to 520.22% [3][9] Pharmaceutical Industry - The pharmaceutical sector is experiencing a "polarized" performance, with over 60 companies disclosing earnings forecasts, about half of which are positive [1][9] - Key performers include: - Zhaoyan New Drug expects a net profit of approximately 233 million to 349 million yuan, a year-on-year increase of 214% to 371% [10] - Shanghai Yizhong anticipates a net profit of 6 million to 7 million yuan, a growth of 760.18% to 903.54% [10] - However, companies like Zhifei Biological are projected to incur significant losses, with an expected net loss of 10.7 billion to 13.7 billion yuan [10][5] Banking Sector - As of January 25, eight listed banks have released earnings reports, with all showing year-on-year growth in net profit [5][11] - Key statistics include: - China Merchants Bank's total assets surpassing 13 trillion yuan, and Industrial Bank exceeding 11 trillion yuan [11] - The highest net profit growth among these banks is from Hangzhou Bank at 12.05%, followed by Shanghai Pudong Development Bank at 10.52% [11] - The growth drivers for banks include improved cost of liabilities and rapid growth in intermediary business income, with Ningbo Bank's net income from fees and commissions increasing by 30.72% [12]

Core Viewpoint - The company, Aidi Pharmaceutical (688488.SH), has announced a strong performance forecast for the fiscal year 2025, highlighting significant revenue growth and a substantial reduction in losses, driven by its dual strategy of "HIV new drugs + human-derived proteins" [1][3] Financial Performance - The company expects a total revenue of approximately 721.01 million yuan for 2025, representing an increase of about 303.21 million yuan, or 72.57% year-on-year [1] - The core product, the innovative anti-HIV drug business, is projected to generate revenue of 285.31 million yuan, reflecting a year-on-year surge of 90.34% [1] - The subsidiary, Nanda Pharmaceutical, is anticipated to contribute approximately 299.84 million yuan in revenue, with a year-on-year increase of 227.38% [2] Loss Reduction and Profitability - The expected net loss attributable to the parent company is estimated to be between 16 million and 24 million yuan, a reduction of approximately 125.20 million to 117.20 million yuan compared to the previous year, marking a decline in loss margin of 88.67% to 83.00% [2] - The adjusted net loss, excluding non-recurring items, is projected to be between 17.20 million and 25.20 million yuan, also showing a significant reduction from the previous year [2] Strategic Initiatives - The impressive performance is attributed to the company's focus on core sectors and the effective implementation of its dual strategy, which has led to a notable increase in gross profit from core operations by approximately 267 million yuan [3] - The company is enhancing its academic promotion efforts and optimizing its commercialization channels to accelerate the market penetration of its core products [3] - Aidi Pharmaceutical is advancing its innovative drug pipeline, with ongoing clinical trials for new HIV integrase inhibitors and long-acting pre-exposure prophylaxis drugs, which are expected to drive long-term growth [3]

Group 1 - Spot gold price has surpassed $5000 per ounce for the first time, with institutions predicting it could rise to $6600 [2] - The recent surge in gold prices is attributed to U.S. President Trump's policies reshaping international relations and investors fleeing sovereign bonds and foreign exchange markets [2] - Last week, gold prices increased by 8.5%, driven by a weakening dollar, which has made gold and silver cheaper for global buyers [2] Group 2 - In the past two weeks, stock ETFs have seen a net outflow of nearly 500 billion yuan, with significant redemptions in broad-based ETFs [3] - The trading volume of stock ETFs has surged, with some broad-based ETFs reaching record highs since their inception [3] Group 3 - The semiconductor sector in A-shares has been active in mergers and acquisitions, with several companies announcing related plans and progress [8] Group 4 - The commercial aerospace sector is experiencing a talent shortage, with investors with relevant experience being highly sought after [9] - The market is facing a significant gap in experienced commercial aerospace investors, leading firms to recruit candidates with adjacent experience [9] Group 5 - Global commodity markets are entering a new super cycle, with fund managers strategically increasing allocations to non-ferrous and chemical products [10] - Factors such as global monetary expansion, a credit crisis in the dollar, and geopolitical conflicts are contributing to this anticipated cycle [10]

Core Viewpoint - Eddie Pharmaceuticals is expected to report a net profit loss of approximately 16 million to 24 million yuan for the fiscal year 2025, indicating a year-on-year reduction in loss margin by about 88.67% to 83% while continuing to record losses for five consecutive years [1] Financial Performance - The company has reported net profit losses of 29.99 million yuan, 124 million yuan, 76.07 million yuan, and 141 million yuan from 2021 to 2024 respectively [1] - The projected non-GAAP net loss for 2025 is estimated to be between 17.2 million and 25.2 million yuan, with a year-on-year reduction in loss margin of approximately 88.41% to 83.02% [1] - Expected operating revenue for 2025 is approximately 721 million yuan, representing a year-on-year increase of about 72.57% [1] Revenue Breakdown - Revenue from innovative anti-HIV drugs is anticipated to be 285 million yuan, reflecting a year-on-year increase of 90.34% [1] - Revenue from the subsidiary Nanda Pharmaceuticals is expected to reach 300 million yuan, with a year-on-year increase of 227.38% [1] Corporate Actions - The company plans to invest 130 million yuan to acquire an additional 22.23% stake in Nanda Pharmaceuticals, increasing its ownership from 51.1256% to 73.36% [3] - The acquisition price is based on an evaluation report, with the assessed value of the 22.23% stake being 130 million yuan, which is approximately 92% higher than its book net asset value of 200 million yuan [3] - This acquisition is seen as a strategic move to strengthen control over Nanda Pharmaceuticals and enhance the company's core competitiveness [3][4] Market Performance - As of January 23, the stock price of Eddie Pharmaceuticals rose by 2.59% to 18.64 yuan per share, with a total market capitalization of approximately 7.843 billion yuan [5] - The stock has seen a cumulative increase of about 157% over the past month [5]